The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV-Naive Women Aged 16-26 Years

Research output: Chapter in Book/Report/Conference proceedingPaper in conference proceeding

Bibtex

@inproceedings{1ca62aba0c4a46c1baca2cab4b0edac0,
title = "The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV-Naive Women Aged 16-26 Years",
abstract = "Background. Human papillomavirus (HPV)-6/11/16/18 vaccine reduces the risk of HPV-6/11/16/18-related cervical intraepithelial neoplasia (CIN) 1-3 or adenocarcinoma in situ (AIS). Here, its impact on CIN1-3/AIS associated with nonvaccine oncogenic HPV types was evaluated. Methods. We enrolled 17,622 women aged 16-26 years. All underwent cervicovaginal sampling and Pap testing at regular intervals for up to 4 years. HPV genotying was performed for biopsy samples, and histological diagnoses were determined by a pathology panel. Analyses were conducted among subjects who were negative for 14 HPV types on day 1. Prespecified analyses included infection of >= 6 months' duration and CIN1-3/AIS due to the 2 and 5 most common HPV types in cervical cancer after HPV types 16 and 18, as well as all tested nonvaccine types. Results. Vaccination reduced the incidence of HPV-31/45 infection by 40.3{\%} (95{\%} confidence interval [CI], 13.9{\%} to 59.0{\%}) and of CIN1-3/AIS by 43.6{\%} (95{\%} CI, 12.9{\%} to 64.1{\%}), respectively. The reduction in HPV-31/33/45/52/58 infection and CIN1-3/AIS was 25.0{\%} (95{\%} CI, 5.0{\%} to 40.9{\%}) and 29.2{\%} (95{\%} CI, 8.3{\%} to 45.5{\%}), respectively. Efficacy for CIN2-3/AIS associated with the 10 nonvaccine HPV types was 32.5{\%} (95{\%} CI, 6.0{\%} to 51.9{\%}). Reductions were most notable for HPV-31. Conclusions. HPV-6/11/16/18 vaccine reduced the risk of CIN2-3/AIS associated with nonvaccine types responsible for similar to 20{\%} of cervical cancers. The clinical benefit of cross-protection is not expected to be fully additive to the efficacy already observed against HPV-6/11/16/18-related disease, because women may have >1 CIN lesion, each associated with a different HPV type.",
author = "Brown, {Darron R.} and Kjaer, {Susanne K.} and Kristjan Sigurdsson and Ole-Erik Iversen and Mauricio Hernandez-Avila and Wheeler, {Cosette M.} and Gonzalo Perez and Koutsky, {Laura A.} and Tay, {Eng Hseon} and Patricia Garcia and Ault, {Kevin A.} and Garland, {Suzanne M.} and Sepp Leodolter and Sven-Eric Olsson and Tang, {Grace W. K.} and Ferris, {Daron G.} and Jorma Paavonen and Marc Steben and Bosch, {F. Xavier} and Joakim Dillner and Joura, {Elmar A.} and Kurman, {Robert J.} and Slawomir Majewski and Nubia Munoz and Myers, {Evan R.} and Villa, {Luisa L.} and Taddeo, {Frank J.} and Christine Roberts and Amha Tadesse and Janine Bryan and Lupinacci, {Lisa C.} and Giacoletti, {Katherine E. D.} and Sings, {Heather L.} and Margaret James and Hesley, {Teresa M.} and Eliav Barra",
year = "2009",
doi = "10.1086/597307",
language = "English",
volume = "199",
publisher = "University of Chicago Press",
number = "7",
pages = "926--935",
booktitle = "Journal Of Infectious Diseases",
address = "United States",

}